Updates are available Correction dated 2024-05-01
Click to view Correction: https://doi.org/10.1038/s41598-024-53036-w
-
Authors
Emma, Rosalia
Fuochi, Virginia
Distefano, Alfio
Partsinevelos, Konstantinos
Rust, Sonja
Zadjali, Fahad
Al Tobi, Mohammed
Zadjali, Razan
Alharthi, Zaina
Pulvirenti, Roberta
Furneri, Pio Maria
Polosa, Riccardo
Sun, Ang
Caruso, Massimo
Li Volti, Giovanni
,
Li Volti, Giovanni
Caruso, Massimo
Emma, Rosalia
Giordano, Antonio
Sun, Ang
Volarevic, Vladislav
Lesmana, Ronny
Poulas, Konstantinos
Distefano, Alfio
Partsinevelos, Konstantinos
Pulvirenti, Roberta
Costa, Aurora
Arsenijevic, Aleksandar
Barliana, Melisa I.
Mesiakaris, Konstantinos
Albalushi, Najwa
Giardina, Chiara
Furnari, Salvatore
-
Funding
Funding for this research was provided by:
ECLAT Srl (REPLICA)
- License Information
-
More Information
Article History
Received: 24 May 2023
Accepted: 10 October 2023
First Online: 30 October 2023
Change Date: 1 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-53036-w
Competing interests
: Riccardo Polosa is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. He has received grants from U-BIOPRED and AIR-PROM, Integral Rheumatology & Immunology Specialists Network (IRIS), Foundation for a Smoke Free World, Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, Merk Sharp & Dohme, Boehringer Ingelheim, Novartis, Arbi Group Srl., Duska Therapeutics, Forest Laboratories, Ministero dell Universita’ e della Ricerca (MUR) Bando PNRR 3277/2021 (CUP E63C22000900006) and 341/2022 (CUP E63C22002080006), funded by NextGenerationEU of the European Union (EU), and the ministerial grant PON REACT-EU 2021 GREEN- Bando 3411/2021 by Ministero dell Universita' e (MUR) – PNRR EU Community. He is founder of the Center for Tobacco Prevention and Treatment (CPCT) at the University of Catania and of the Center of Excellence for the Acceleration of Harm Reduction at the same university. He receives consultancy fees from Pfizer, Boehringer Ingelheim, Duska Therapeutics, Forest Laboratories, CV Therapeutics, Sermo Inc., GRG Health, Clarivate Analytics, Guidepoint Expert Network, and GLG Group. He receives textbooks royalties from Elsevier. He is also involved in a patent application for ECLAT Srl. He is a pro bono scientific advisor for Lega Italiana Anti Fumo (LIAF) and the International Network of Nicotine Consumers Organizations (INNCO); and he is Chair of the European Technical Committee for Standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). Giovanni Li Volti is currently elected Director of the Center of Excellence for the acceleration of HArm Reduction (CoEHAR). The other authors have no relevant financial interests to disclose.
